<DOC>
	<DOCNO>NCT01840540</DOCNO>
	<brief_summary>To determine safety toxicity intra-arterial infused autologous adipose derive mesenchymal stromal ( stem ) cell patient vascular occlusive disease kidney .</brief_summary>
	<brief_title>MSC Occlusive Disease Kidney</brief_title>
	<detailed_description>Individuals unilateral arterial occlusive disease treat injured kidney autologous cell .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Renal Artery Obstruction</mesh_term>
	<mesh_term>Hypertension , Renovascular</mesh_term>
	<criteria>4.1 Inclusion Criteria 1 . Are age 40 80 year old . 2 . Advanced vascular occlusive disease ( atherosclerosis ) affect one kidney : define ) loss parenchymal volume renal blood flow ( measure MDCT previously describe ( 17 ) and/or duplex ultrasound velocity 300 cm/sec affect kidney infuse MSC 's . 3 . Have serum creatinine 2.5 mg/dL 4 . Have nocontraindications angiography : severe contrast allergy 5 . Have contraindication MR evaluation : e.g . pacemaker magnetically active metal fragment , claustrophobia 6 . Ability comply protocol 7 . Competent able provide write informed consent 4.2 Exclusion Criteria 1 . Advanced CKD : Stage 5 ( two kidney eGFR &lt; 15 ml/min/1.73 m2 ) contralateral renal artery occlusion/stenosis 75 % ESRD require dialysis 2 . Clinically significant abnormality laboratory examination , include Bilirubin ( &gt; 2 x normal ) , platelet ( &lt; 100 thousand ) , potassium ( &gt; 5.5 mEq/L ) , sodium ( &lt; 130 mEq/L ) , ALT AST 2 x normal , Prothrombin time ( INR &gt; 1.4 ) , Hemoglobin &lt; 10.0 g/dL . 3 . Clinically significant medical condition within six month administration MSCs : e.g . myocardial infarction , active angina , congestive heart failure ) would , opinion investigator , compromise safety patient . 4 . Specific exclusion : 1 . Clinical history deep vein thrombosis within three month MSC administration 2 . Uncontrolled hypertension ( Systolic BP &gt; 180 mmHg despite therapy ) 3 . Active infection 4 . Reduced ejection fraction ( 30 % ) 5 . Evidence hepatitis B , C , HIV 6 . Diabetes treat insulin and/or glucose lower agent 7 . Anemia ( Hgb &lt; 10 g/dL ) 8 . Regular use potentially renotoxic drug , e.g . nonsteroidal antiinflammatory agent ( NSAID 's ) : ( &gt; 2 x weekly ) 5 . History cancer include melanoma ( exception localize skin cancer ) 6 . Investigational drug exposure within thirty ( 30 ) day baseline 7 . Beck 's depression score 16 8 . Pregnant breast feeding . 9 . History clinically significant autoimmunity previous example fatdirected autoimmunity</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>renal artery stenosis</keyword>
	<keyword>renovascular hypertension</keyword>
	<keyword>ischemic nephropathy</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>